Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
3.650
-0.180 (-4.70%)
At close: Jul 30, 2025, 4:00 PM
3.690
+0.040 (1.10%)
After-hours: Jul 30, 2025, 7:37 PM EDT
Altimmune Revenue
Altimmune had revenue of $5.00K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $20.00K, down -95.12% year-over-year. In the year 2024, Altimmune had annual revenue of $20.00K, down -95.31%.
Revenue (ttm)
$20.00K
Revenue Growth
-95.12%
P/S Ratio
15,004.79
Revenue / Employee
$339
Employees
59
Market Cap
296.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.00K | -406.00K | -95.31% |
| Dec 31, 2023 | 426.00K | 494.00K | -726.47% |
| Dec 31, 2022 | -68.00K | -4.48M | -101.54% |
| Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
| Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| Novartis AG | 55.19B |
| AstraZeneca | 54.98B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
ALT News
- 11 days ago - ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 21 days ago - Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) - GlobeNewsWire
- 4 weeks ago - Altimmune's Fatty Liver Candidate Faces Differentiation Doubts - Benzinga
- 4 weeks ago - Altimmune: Deciphering The MASH Crash (Rating Upgrade) - Seeking Alpha
- 4 weeks ago - Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide - Seeking Alpha
- 4 weeks ago - Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
- 4 weeks ago - Altimmune's weight-loss drug meets main goal in fatty liver disease trial - Reuters
- 4 weeks ago - Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH - GlobeNewsWire